We investigated the impact of donor type on post-relapse survival (PRS) in 85 patients with hematological relapse after their first allogeneic hematological stem cell transplantation (allo-HSCT) for hematological malignancy. The median follow-up was 64 months among survivors. Both 3-year overall survival and 3-year PRS were similar in haploidentical donor (HID) and matched sibling donor (MRD) transplantation (13.0% ± 4.7% vs 19.4% ± 7.1%, P = 0.913 and 7.7 ± 3.9% vs 9.7 ± 5.3%, P = 0.667). Higher rates of post-relapse grade II-IV and III-IV acute GvHD (aGvHD) were observed in HID transplantation patients. A higher cumulative incidence of post-relapse extensive chronic GvHD was also observed for HID transplantation patients. Multivariate analyses confirmed that treatment including donor lymphocyte infusion (DLI), late relapse 41 year, and in first CR at transplantation were associated with superior PRS (P = 0.012, hazard ratio (HR) = 0.527 (0.320 − 0.866)); P = 0.033, HR = 0.534 (0.300 − 0.952) and P = 0.046, HR = 0.630 (0.400 − 0.992). The data suggest that post-relapse outcomes are comparable in HID and MRD transplantation, and that DLI is safe for relapsed patients after haploidentical transplantation. 3 Post-relapse survival is poor and dependent on multiple factors, including disease type, patient age, the interval between transplantation and relapse and donor type. A previous Japanese study of acute leukemia patients demonstrated that unrelated donor transplantation results in lower post-relapse overall survival (OS) than related donor transplantation.
INTRODUCTION
Relapse after allogeneic hematological stem cell transplantation (allo-HSCT) is the main cause of death from hematological malignancies, especially in high-risk patients. [1] [2] [3] The Center for International Blood and Marrow Transplant Research has reported that relapse accounts for 42% of all post-transplant deaths in HLA-identical sibling donor transplantation and 33% of all deaths in unrelated donor transplantation. 3 Post-relapse survival is poor and dependent on multiple factors, including disease type, patient age, the interval between transplantation and relapse and donor type. A previous Japanese study of acute leukemia patients demonstrated that unrelated donor transplantation results in lower post-relapse overall survival (OS) than related donor transplantation. 4 Haploidentical donors (HIDs), who are universally available donors, have been applied in transplantation for individuals who lack an HLA-matched sibling donor or are in need of rapid transplantation. Similar OS and post-relapse survival (PRS) rates have been reported in haploidentical transplant recipients as a result of granulocyte CSF (G-CSF) modulated allografts, aggressive GvHD prophylaxis and post-transplant cyclophosphamide (PTCy). [5] [6] [7] [8] [9] Favorable outcomes led to more HID transplant recipients, and in Europe the number of haploidentical HSCTs has more than doubled since 2010. 10 Although HIDs are associated with post-transplant outcomes, such as GvHD, 6, 8 few studies have explored the post-relapse outcomes between HIDs and other types of donors. The loss of mismatched HLA, which is observed in haploidentical transplantation, 11, 12 but not matched transplantation, indicates that mechanisms of relapse vary between HID transplantation and transplantation from other donor types. Furthermore, because approaches to relapse tend to be decided on an individual basis, and treatments for relapse range from withdrawal of immunosuppressants to second allogeneic transplantation, post-relapse management for haploidentical recipients differs from that of others. For example, haploidentical recipients may be less prone to receiving donor lymphocyte infusion (DLI) due to the risk of GvHD.
We performed a retrospective cohort analysis comparing patients who underwent T-cell-replete allo-HSCT from HIDs and matched sibling donors (MRDs) for hematological malignancies at our institution, to explore possible factors associated with post-relapse outcomes.
PATIENTS AND METHODS Patients
Between Jan 1, 2003 and December 31, 2008, 1107 consecutive patients with hematological malignancies received T-cell-replete allo-HSCT at Peking University Institute of Hematology. A total of 126 recipients had hematological relapse after allo-HSCT. Patients who underwent a second allo-HSCT or received palliative treatment were excluded. Patients who received allografts from cord blood or unrelated donors were excluded. The remaining 85 patients who received treatment for hematological relapse were included in this retrospective study, including 54 HID transplant recipients and 31 MRD transplant recipients. The study protocol was approved by the Institutional Review Board of Peking University. All patients provided written informed consent for the procedure.
Conditioning regimen and supportive care
The transplantation procedure was described in a previous study. 13 For HID-HSCT, the busulfan (BU)-based conditioning regimen included 1 /d, intravenous, days − 10 and − 9), BU (4 mg/kg/d, oral, days − 8 to − 6), cyclophosphamide (CY; 1.8 g/m 2 /d, days − 5 and − 4), anti-thymoglobulin (ATG; 1.5 or 2.5 mg/kg/d, days − 5 to − 2), and semustine (Me-CCNU; 250 mg/m 2 , day − 3). For MRD-HSCT, patients received hydroxyurea (Hu) (40 mg/kg, twice oral, day 10), a lower dose of Ara-C (2 g/m 2 /d, intravenous, day − 9), and no ATG, but otherwise an identical regimen to haploidentical patients. All patients received G-CSF-mobilized bone marrow (BM) cells plus PBSC. In both cohorts, GvHD prophylaxis consisted of cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate (MTX). 
Definition of GvHD
Both acute GvHD (aGvHD) and chronic GvHD (cGvHD) were diagnosed and graded according to the traditional criteria.
16,17 DLI-associated GvHD was diagnosed as acute or chronic according to the clinical features of involved organs rather than the onset time after modified DLI. 14 
Statistical analysis
Descriptive statistics were used to summarize patient characteristics. The Mann-Whitney U rank sum test, chi-square test or Fisher's exact test was used for two sample comparisons. All tests were two-sided. The Kaplan-Meier approach was used to estimate time-to-event analyses including OS and PRS. The log-rank test was used to identify prognostic factors and a Cox model to assess the relative impact of previously defined risk factors in multivariate analyses. 18 The forced factor (HID vs MRD) and all factors with Po 0.2 in the univariate analysis were included in a multivariate regression. Po0.05 was considered significant. Cumulative incidence tests were applied to estimate the competing risk for GvHD. 19 Death was regarded as a competing risk for GvHD. Data analyses were conducted primarily with SPSS software (version 13.0, SPSS Inc., Chicago, IL, USA), and R software (version 2.6.1; http://www.r-project.org) was used for competing risk analysis.
RESULTS

Patient characteristics
Patient and transplantation characteristics are shown in Table 1 . Patients in the HID group were significantly younger than those in the MRD group. Faster neutrophil engraftment was observed in the HID group. Gender, distribution of disease, disease risk and other variables were comparable in both cohorts. The median follow-up after transplantation among survivors in both groups was 64 months. The median follow-up after relapse among survivors in both groups was 39 months (range, 64-75 months for MRD and 4-60 months for HID).
Post-relapse treatment and clinical outcomes Most patients received chemotherapy or chemotherapy followed by DLI as the relapse treatment ( 8 /kg) for MRD, P = 0.323). After treatment, 34 (40.0%) patients achieved CR. The CR rate, CR duration and re-relapse rate were comparable between the two groups ( Table 2) . Among patients receiving DLI in the two groups, the CR rate was similar (57.1% in MRD vs 55.6% in HID, P = 0.907). The CR rate was significantly lower in patients who did not receive DLI compared to those who received DLI (7.1 vs 56.1%, P = 0.000). In addition, patients in CR1 at transplantation had a higher CR rate after relapse treatment than non-CR1 patients (50.0 vs 28.2%, P = 0.041). No significant association was found between relapse time and CR rate. In multivariable analysis, CR1 Abbreviations: AL = acute leukemia; BM = bone marrow; BU = busulfan; CMML = chronic myelomonocytic leukemia; CY = cyclophosphamide; Flu = fludarabine; HID = haploidentical donor; MDS = myelodysplastic syndrome; MNC = mononuclear cell; MRD = matched related donor; RAEB = refractory anemia with excess blasts.
Comparable post-relapse outcomes between HID and MRD HSCT Y-R Ma et al and DLI were beneficial factors for CR (P = 0.014 and P = 0.000, respectively). Before re-relapse, patients had a median CR duration of 3 months (range, 1-15 months). MRD transplant recipients had a higher re-relapse rate than HID transplant recipients, 92.3 vs 66.7%, respectively (P = 0.195). Among patients achieving CR after post-transplant relapse, a higher rate of re-relapse was observed in patients who relapsed within 1 year after allo-HSCT (88.0 vs 44.4%, P = 0.029). Grade II to IV aGvHD was observed in 12.9% of MRD transplant recipients and 27.8% of HID transplant recipients before relapse (P = 0.056). Extensive cGvHD was observed in 6.5 and 13.0% of MRD and HID transplant patients before relapse (P = 0.465). The median time between the first onset of aGvHD and relapse was 284 days (range, 6-1877 days). The median time between the first onset of cGvHD and relapse was 213.5 days (range, 8-1721 days). The cumulative incidences of 100-day post-relapse grade II-IV aGvHD and III-IV aGvHD were higher in the HID group than the MRD group (29.6% and 18.5% vs 6.5% and 3.2%, respectively, P = 0.010 and P = 0.032). A higher cumulative incidence of 1-year post-relapse extensive cGvHD was observed in HID transplant recipients than MRD transplant recipients (22.6 vs 6.5%, P = 0.069). No GvHD-related deaths were observed. The rates of 100-day post-relapse grade II-IV aGvHD and III-IV aGvHD were not significantly different between the DLI group and non-DLI group (22.8% and 17.5% vs 17.9% and 3.6%, respectively, P = 0.635 and P = 0.063). An increased incidence of 1-year post-relapse extensive cGvHD was observed in patients who received therapeutic DLI compared to those who did not (26.3 vs 0%, P = 0.004). Among DLI patients, increased rates of post-relapse grade II-IV aGvHD, III-IV aGvHD and extensive cGvHD were also observed in HID group (100-day II-IV aGvHD, 33.3 vs 4.8%, P = 0.011; 100-day III-IV aGvHD, 25.0 vs 4.8%, P = 0.041; 1-year extensive cGvHD, 36.1 vs 9.5%, P = 0.041). Other factors, including donor sex, relapse time, and CD34 counts, did not significantly correlate with post-relapse GvHD.
OS and PRS
Among relapsed patients, the overall survival at 3 years was 19.4 ± 7.1% for the MRD group and 13.0 ± 4.7% for the HID group (P = 0.913; Figure 1a) . The post-relapse survival at 3 years was 9.7 ± 5.3% for the MRD group and 7.7 ± 3.9% for the HID group (P = 0.667; Figure 1b) . Two MRD transplant recipients and six HID transplant recipients were alive. Disease progression or relapse was the major cause of death. Accordingly, 93.1% of MRD transplant recipients and 93.8% of HID transplant recipients died in non-remission, whereas two patients with CR in the HID group died from infection. For patients receiving therapeutic DLI, the 3-year OS was similar between the two groups (23.8 ± 9.3% for MRD and 14.4 ± 6.0% for HID, P = 0.768). The 3-year PRS was 9.5 ± 6.4% for the MRD group and 11.2 ± 5.6% for the HID group (P = 0.974).
In addition to donor type, other factors that may affect OS and PRS were observed. The 3-year OS was not significantly different between DLI and non-DLI patients (18.0 ± 5.1% vs 8.9 ± 5.7%, P = 0.203). The 3-year PRS for patients who received DLI was 10.5 ± 4.2%, compared with 3.9 ± 3.8% for patients who did not Abbreviations: DLI = donor lymphocyte infusion; TKI = tyrosine kinase inhibitor. receive DLI (P = 0.003). None of the patients with the Ph chromosome remained alive. The 3-year OS and PRS were both 0% for Ph+ diseases. Factors significantly associated with shorter post-transplantation OS based on multivariable analysis included time to relapse ⩽ 1 year and ⩾ CR1 before transplantation (Table 3 ). In the Cox regression model, time to relapse ⩽ 1 year, ⩾ CR1 before transplantation and not receiving DLI after relapse were independent predictors of post-relapse mortality. After treatment, patients who regained CR had higher 3-year OS and PRS (33.5% ± 8.2% vs 3.9% ± 2.7%, P = 0.000 and 21.4% ± 7.4% vs 0%, P = 0.000, respectively). Among patients with CR, 3-year OS and PRS were similar between the two groups (30.8% ± 12.8% and 23.1% ± 11.7% in MRD vs 30.3% ± 10.3% and 20.4% ± 9.7% in HID, P = 0.866 and P = 0.778, respectively). Patients who had post-relapse II-IV or III-IV aGvHD after relapse did not have higher OS and PRS. However, patients with extensive cGvHD after relapse had higher 3-year OS and PRS than patients with limited or no cGvHD (35.7% ± 12.8% vs 11.2% ± 3.8%, P = 0.002 and 35.7% ± 12.8% vs 3.1% ± 2.1%, P = 0.001).
DISCUSSION
Relapse after transplantation still remains a challenge, particularly because relapsed diseases are more likely to be aggressive and resistant, and few patients achieve durable remission using current strategies. In recent years, researchers have reported the benefits and disadvantages of stratifying and selecting suitable strategies for relapsed patients, but few studies have focused on donor type, especially HIDs. Because the mechanism and treatment of relapse after haploidentical transplantation may differ from matched donor transplantation, we reviewed the outcomes of relapsed hematological malignancies post HSCT at our institution to compare HID with MRD transplantation.
Our study focused on a population from long enough before the study to ensuring adequate follow-up time among survivors. The 3-year OS and 3-year PRS were similar to previous reports. [20] [21] [22] The patient and transplantation characteristics were balanced between the two groups, except that patients in the MRD group were older, as elder patients were more likely to have a matched sibling donor. However, age was not independently associated with OS or PRS in multivariable analyses.
In our study, most of the relapsed patients died from disease progression. Patients who received MRD and HID transplants underwent similar relapse treatments and had comparable CR and re-relapse rates, indicating comparable OS and PRS. Limited data is available on the analysis of donor type for relapsed patients. Matsunmoto et al. reported that unrelated donors have worse survival than related donors (both matched and mismatched; hazard ratio (HR) = 1.76 (1.10 − 2.80)). 4 In a study of 237 patients in a BMT program, 1-year PRS for HID, MRD, and matched unrelated donor (MUD) were 17%, 46%, and 40%, respectively. 23 In our study, the 1-year PRS for the HID and MRD groups with non-DLI treatment were 0 and 20.0% (P = 0.435). Non-inferior survival was observed in HID transplant patients who received therapeutic DLI, with 1-year PRS of 26.9% compared with 28.6% in MRD transplant patients. The discordance with our findings may reflect differenczaes in the distribution of diseases, conditioning, treatment for relapse, and GvHD prophylaxis. However, the most important factor was the use of different therapies. In the previous study, a lower proportion of HID transplant patients received DLI as post-relapse treatment compared with MRD or MUD transplant patients. In contrast, the proportion of patients receiving DLI was similar between the HID and MRD groups in our study. We speculated that the reduced use of DLI after HID transplantation may have contributed to inferior survival. DLI was has been reported to be associated with enhanced survival for relapsed diseases, 4, 20 and previous studies at our institution have shown that DLI is more effective than chemotherapy alone. 24 However, the use of DLI has been implicated in an increased risk of GvHD. In this study, higher incidences of grade III-IV and III-IV aGvHD were observed in the HID group, and a higher incidence of extensive cGvHD was also observed with HID transplantation. However, the cases were well controlled and no GvHD-related deaths occurred. Importantly, the current study included subjects before 2009 when patients in both groups were given 2-4 weeks of immunosuppressants. Our recent study demonstrated that a longer immunosuppressant duration of 6-8 weeks in HID transplantation results in less GvHD, but not increased relapse. 25 The observation that post-relapse GvHD is more common for HID transplantation was consistent with our HID patterns. Furthermore, disease relapse or progression was the leading cause of mortality after relapse. Notably, our subjects with extensive cGvHD post-relapse had better PRS, which is in line with previous reports demonstrating that the occurrence of cGvHD is the main factor determining improved survival from relapse. 3 Other factors influencing post-relapse survival were detected in multivariable analyses. We demonstrated that patients who relapsed within 1 year had worse survival, which confirms results from other studies. 4, 20, 22 Previous studies showed that time to relapseo 136 days, 20 o180 days 4 and o 6.9 months 22 is associated with worse PRS. Moreover, we show that disease status at the time of relapse is an independent predictor of post-relapse survival. Patients in CR1 had higher survival chances of survival than those in CR2, CR3 or non-remission. Investigators from EBMT reported that late CR (CR2/CR3) is an adverse factor in patients with ALL, 22 which is in accordance with our results. The 3-year OS and PRS for the total population were 15.4 ± 4.0% and 8.4 ± 3.1%. The disappointing outcomes of post-HSCT relapse may be due to multiple factors. First, some patients received chemotherapy alone. Among patients receiving DLI, most received only one dose. Minimal residual disease (MRD)-guided DLI currently used in our center may improve post-relapse outcomes. Abbreviations: DLI = donor lymphocyte infusion; HID = haploidentical donor; HR = hazard ratio; OS = overall survival; PRS = post-relapse survival; MRD = matched related donor.
Comparable post-relapse outcomes between HID and MRD HSCT Y-R Ma et al Second, patients who received a second allo-HSCT were excluded from this study. Second allo-HSCT has been reported to be superior to chemotherapy 26 and may provide long-term PRS. We acknowledge several limitations of our retrospective cohort study. Patients who underwent HID transplantation were younger, which implies better performance status and endurance of intensified treatment. 32 In addition, there is the possibility of selection bias regarding which patients received treatment in this retrospective study. Patients with severe GvHD or comorbidities may decline subsequent treatment when they relapse. Moreover, we failed to compare outcomes of HID and MRD transplantation with contemporary MUD transplantation due to an insufficient number of cases. Therefore, a prospective, multicenter trial evaluating different types of donors, including HIDs, MRDs and MUDs, may be necessary to readdress this issue.
In conclusion, our results demonstrate that MRD and HID-HSCT achieve comparable outcomes for post-transplant relapsed patients. Accordingly, we recommend active and reasonable application of DLI in haploidentical transplants. Future studies on reducing the risks of relapse and novel therapeutic approaches [33] [34] [35] for treating post-transplantation relapse are warranted.
